University of Wisconsin-Madison

Migration, Crosslink

📖

University of Wisconsin-Madison

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-university-of-wisconsi

📖 Wiki Page

institution2946 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~49,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging</td>
</tr>
</table>

University of Wisconsin-Madison

Introduction

The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Wisconsin-Madison</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Madison, Wisconsin, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1848</td>
</tr>
<tr>
<td class="label">Students</td>
<td>~49,000</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.wisc.edu" target="_blank">https://www.wisc.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Neurodegeneration, Biomarkers, Neuroimaging</td>
</tr>
</table>

University of Wisconsin-Madison

Introduction

The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and related conditions.

The institution's location in Madison, Wisconsin, has fostered a unique research environment that combines access to diverse patient populations, strong academic resources, and a collaborative culture that has produced landmark discoveries in neurodegenerative disease research. The Wisconsin Alzheimer's Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer Prevention (WRAP) represent some of the most influential programs in the field.

Historical Development

Foundation and Early Growth

The University of Wisconsin-Madison was founded in 1848 as the state's land-grant university. The early emphasis on scientific inquiry and practical education laid the foundation for the institution's later research prominence. The Department of Neurology was established in the mid-20th century, marking the beginning of systematic neuroscience research.

Development of Neuroscience Research

Throughout the latter half of the 20th century, UW-Madison built its neuroscience research capabilities through strategic hiring and infrastructure investments. Key developments include:

1970s: Establishment of the neuroscience graduate program
1980s: Construction of the Waisman Center for brain research
1990s: Launch of the Alzheimer's disease research program
2009: Establishment of the Wisconsin Alzheimer's Disease Research Center
2010s: Growth of the Wisconsin Registry for Alzheimer Prevention

The Wisconsin Alzheimer's Disease Research Center

The Wisconsin Alzheimer's Disease Research Center (WADRC) was established in 2009 with funding from the National Institute on Aging, becoming one of 33 NIH-funded Alzheimer's Disease Research Centers. The center has made seminal contributions to understanding preclinical Alzheimer's disease and identifying biomarkers that enable early detection[@johnson2018].

The WADRC's mission encompasses:

Research: Basic and clinical research on Alzheimer's disease
Training: Education of the next generation of researchers
Outreach: Community engagement and education
Clinical care: Assessment and care for patients and families

Research Infrastructure

Campus and Facilities

UW-Madison's research facilities are among the most advanced in the world. The campus features purpose-built research space designed for interdisciplinary collaboration.

Wisconsin Alzheimer's Disease Research Center

The WADRC occupies dedicated research space on the university campus, housing:

Clinical research unit: Outpatient facilities for participant evaluation
Biomarker laboratory: CSF and blood processing and analysis
Neuroimaging suite: MRI and PET scanner access
Data management: Secure data storage and analysis infrastructure

Waisman Center

The Waisman Center is one of the nation's premier centers for developmental disabilities and neurodegenerative disease research. Established in 1973, it provides:

Neuroimaging facilities: Advanced MRI and PET capabilities
Stem cell research: Induced pluripotent stem cell facility
Behavioral assessment: Specialized testing environments
Core facilities: Shared resources for researchers

Center for Neurodegeneration and Repair

The Center for Neurodegeneration and Repair (CNR) brings together researchers from multiple departments to study:

Parkinson's disease mechanisms and therapeutics
Alzheimer's disease pathogenesis
Traumatic brain injury and chronic neurodegeneration
Alcohol-related brain damage

Research Centers and Programs

| Center | Focus | Director |
|--------|-------|----------|
| Wisconsin Alzheimer's Disease Research Center | AD biomarkers and clinical research | Dr. Sterling C. Johnson |
| Wisconsin Registry for Alzheimer Prevention | Preclinical AD and lifestyle factors | Dr. Mark A. Sager |
| Center for Neurodegeneration and Repair | Multiple neurodegenerative diseases | Dr. Matthew R. Anderson |
| Waisman Center | Neurodevelopment and neurodegeneration | Dr. Albee Messing |
| Center for Sleep and Consciousness | Sleep and brain health | Dr. Giulio Tononi |

Alzheimer's Disease Research Program

Overview

Mermaid diagram (expand to render)

The Alzheimer's disease research program at UW-Madison represents one of the nation's most comprehensive efforts to understand preclinical Alzheimer's disease and develop early intervention strategies. The program's focus on early detection has yielded critical insights into disease progression and risk factors["@johnson2020"].

Current Research Directions

Biomarker Studies

Researchers at UW-Madison have made substantial contributions to biomarker research:

Cerebrospinal Fluid Biomarkers

Amyloid-beta (Aβ42, Aβ40) measurement
Total tau and phospho-tau analysis
Neurofilament light chain as neuronal injury marker
Novel biomarker discovery through proteomics

Blood-Based Biomarkers

Development of plasma Aβ assays
Ultra-sensitive tau measurement techniques
Exploration of extracellular vesicle biomarkers

Imaging Biomarkers

Amyloid PET with florbetapir and flutemetamol
Tau PET with flortaucipir
Structural MRI for hippocampal volume
Functional connectivity MRI[@bendlin2019]

Risk Factor Research

The program has identified multiple modifiable risk factors:

Cardiovascular health: Blood pressure, diabetes, and vascular risk
Lifestyle factors: Exercise, diet, and cognitive engagement
Metabolic factors: Obesity and metabolic syndrome
Sleep quality: Sleep disorders and circadian dysfunction[@koscik2021]

Clinical Research

The clinical research program encompasses:

WRAP study: Wisconsin Registry for Alzheimer Prevention
Treatment trials: Disease-modifying and symptomatic therapies
Prevention studies: Trials in cognitively normal individuals
Observational studies: Natural history and biomarker studies

The Wisconsin Registry for Alzheimer Prevention (WRAP)

The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer's disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years[@sager2019].

WRAP has contributed to major findings including:

Identification of earliest biomarkers of preclinical Alzheimer's
Understanding of lifestyle and genetic risk factors
Development of cognitive reserve measures
Characterization of subjective cognitive decline

Notable Publications

Research from UW-Madison has appeared in leading journals:

Neurology
Alzheimer's & Dementia
Journal of Nuclear Medicine
Neurobiology of Aging
Nature Reviews Neurology

Parkinson's Disease Research Program

Overview

The Parkinson's disease research program at UW-Madison has developed into a comprehensive effort spanning basic science, clinical research, and therapeutic development. The program benefits from the institution's expertise in protein aggregation, dopamine biology, and neuroimaging.

Research Focus Areas

Alpha-Synuclein Biology

Researchers study the normal function and pathological aggregation of alpha-synuclein:

Aggregation mechanisms: Understanding fibril formation and propagation
Cellular models: In vitro and in vivo models of toxicity
Strain characterization: Distinct aggregate conformations

Dopamine Neurobiology

The program investigates dopamine neuron biology:

Survival mechanisms: Factors promoting dopaminergic neuron survival
Degeneration pathways: Understanding cell death mechanisms
Therapeutic targets: Novel neuroprotective approaches

Clinical Research

The clinical research program includes:

Movement Disorder Clinic: Comprehensive patient care
Deep brain stimulation: Surgical program and programming
Clinical trials: Novel therapeutic agents and devices
Biomarker studies: Identification of progression markers

Non-Motor Symptoms Research

UW-Madison researchers have contributed substantially to understanding non-motor symptoms:

Sleep disorders: REM sleep behavior disorder, insomnia
Cognitive impairment: Executive dysfunction and dementia
Psychiatric manifestations: Depression, anxiety, psychosis
Autonomic dysfunction: Gastrointestinal and cardiovascular issues

Key Researchers

Leadership

| Researcher | Position | Focus Area |
|------------|----------|------------|
| Dr. Sterling C. Johnson | Professor, WADRC Director | Preclinical AD biomarkers, neuroimaging |
| Dr. Barbara B. Bendlin | Associate Professor | Lifestyle factors, biomarkers, neuroimaging |
| Dr. Matthew R. Anderson | Chair of Neurology | Parkinson's disease, movement disorders |
| Dr. Mark A. Sager | Professor | WRAP, cognitive aging |
| Dr. Sanjay Asthana | Professor | AD clinical trials, biomarkers |
| Dr. Joseph R. W. Ryman | Associate Professor | Alpha-synuclein biology |

Faculty Members

Dr. Kimberly A. Mueller: Cognitive aging, intervention studies
Dr. Aaron M. P. Greene: Neuroimaging, computational methods
Dr. Lindsay R. Clark: Blood biomarkers, precision medicine
Dr. Hans J. T. Johnson: Sleep and neurodegeneration

Sterling C. Johnson Laboratory

Dr. Sterling Johnson leads the WADRC and has been instrumental in characterizing preclinical Alzheimer's disease through the WRAP cohort. His research has focused on identifying biomarker changes that occur decades before clinical symptoms appear. The Johnson laboratory has published extensively on the relationship between amyloid and tau pathology and cognitive decline, demonstrating that biomarker changes can predict future cognitive impairment even in cognitively normal individuals[@johnson2018][@johnson2020]. Current research explores multi-modal biomarker approaches combining imaging, CSF, and blood-based measures.

Barbara B. Bendlin Research Program

Dr. Bendlin's research examines how lifestyle factors influence Alzheimer's disease biomarkers and risk. Her work has shown that cardiovascular health, exercise, diet, and other modifiable factors can influence brain aging and Alzheimer's disease pathology[@bendlin2019][@koscik2021]. The Bendlin laboratory uses neuroimaging and biomarker approaches to understand how lifestyle interventions may protect against neurodegeneration.

Matthew R. Anderson Parkinson's Research

Dr. Anderson chairs the Department of Neurology and leads the Parkinson's disease research program. His research focuses on understanding the mechanisms of dopaminergic neuron degeneration and developing neuroprotective strategies. The Anderson laboratory investigates alpha-synuclein biology, mitochondrial dysfunction, and neuroinflammation in Parkinson's disease pathogenesis.

Wisconsin Registry for Alzheimer Prevention (WRAP)

The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer's disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years[@sager2019].

Study Design and Population

WRAP participants are recruited from throughout Wisconsin, with an emphasis on including individuals with a family history of Alzheimer's disease. The cohort includes:

Age range: 40-65 years at enrollment
Cognitive status: Cognitively normal at baseline
Family history: Approximately 70% have a parent or sibling with AD
Assessment schedule: Comprehensive testing every 2 years

Key Findings

WRAP has contributed to major findings including:

Identification of earliest biomarkers of preclinical Alzheimer's
Understanding of lifestyle and genetic risk factors
Development of cognitive reserve measures
Characterization of subjective cognitive decline
Sleep and circadian influences on biomarkers[@postler2023]

Biomarker Contributions

WRAP researchers have made significant contributions to biomarker science:

Amyloid PET Imaging: Longitudinal amyloid PET imaging has characterized the temporal relationship between amyloid deposition and downstream tau pathology and cognitive decline[@cody2023]. Studies show that amyloid accumulation begins decades before symptoms and follows a predictable trajectory.

CSF Biomarkers: WRAP has contributed to understanding how CSF biomarkers change in preclinical AD, including amyloid, tau, and neurofilament light chain measurements[@bendlin2019]. These studies have informed biomarker cutoff values and diagnostic criteria.

Blood Biomarkers: UW-Madison researchers have been at the forefront of developing blood-based biomarkers, comparing plasma and CSF measures and validating ultra-sensitive assays for clinical use.

Training and Education

Graduate Programs

UW-Madison offers comprehensive neuroscience training:

PhD in Neuroscience: Four-year program with neurodegeneration track
PhD in Comparative Biomedical Sciences: Translational research focus
Medical Scientist Training Program: MD/PhD training

Clinical Training

Neurology residency: Four-year program with movement disorders track
Behavioral neurology fellowship: Cognitive disorders training
Movement disorders fellowship: Advanced clinical training

Postdoctoral Training

The institution supports postdoctoral researchers through:

Individual fellowship opportunities
Institutional training grants
Career development programs

International Collaborations

Academic Partnerships

UW-Madison maintains collaborations with leading institutions:

Washington University St. Louis: ADNI and biomarker studies
University of Minnesota: Regional collaboration
University of California, San Francisco: Parkinson's research
Mayo Clinic Rochester: Clinical research partnerships
Banner Alzheimer's Institute: Prevention trials

Research Consortia

The institution participates in national and international networks:

Alzheimer's Disease Neuroimaging Initiative (ADNI): Founding member
Alzheimer's Disease Sequencing Project: Genetic studies
International Parkinson's Disease Genomics Consortium: Genetic research
Knight Alzheimer Disease Research Centers: Collaborative network

Industry Partnerships

UW-Madison collaborates with pharmaceutical companies:

Clinical trials: Multiple therapeutic programs
Biomarker development: Companion diagnostic development
Preclinical collaboration: Drug discovery partnerships

Achievements and Impact

Major Contributions

UW-Madison researchers have made significant contributions:

Preclinical AD characterization: Defining earliest disease stages

Biomarker development: Pioneering CSF and imaging approaches

Risk factor identification: Lifestyle and genetic determinants

Cognitive reserve research: Understanding resilience mechanisms

Research Output

The institution's research productivity includes:

150+ publications annually in neurodegenerative disease research
40+ active clinical trials
$40+ million in annual research funding

Future Directions

Strategic Priorities

UW-Madison has identified key research priorities:

Early intervention: Development of prevention strategies

Precision medicine: Biomarker-guided treatment approaches

Lifestyle interventions: Non-pharmacological risk reduction

Digital health: Remote monitoring and digital biomarkers

Emerging Research Areas

Alpha-synuclein PET: Development of imaging agents
Multi-omic approaches: Integration of genomic, proteomic data
Cell therapy: Stem cell approaches to neuronal replacement
AI/ML: Computational models for prediction and diagnosis

Clinical Services

Outpatient Services

UW-Madison provides specialized clinics:

Memory Disorders Clinic: Comprehensive dementia evaluation
Movement Disorder Clinic: Parkinson's disease care
Sleep Disorders Clinic: Sleep and neurodegeneration
General Neurology Clinic: Comprehensive care

Diagnostic Services

Neuroimaging: MRI, CT, PET
Neuropsychology: Comprehensive cognitive testing
Neurophysiology: EEG, EMG
Laboratory: CSF analysis, genetic testing

Clinical Trials Program

UW-Madison maintains an active clinical trials program for neurodegenerative diseases, participating in trials across all phases of drug development.

Alzheimer's Disease Trials

The WADRC and Memory Disorders Clinic participate in numerous Alzheimer's disease clinical trials:

Disease-Modifying Therapies: UW-Madison has been a key site for anti-amyloid antibody trials, including lecanemab and donanemab studies. The institution contributed significantly to the CLARITY-AD and TRAILBLAZER trials, evaluating whether amyloid removal translates to clinical benefit.

Tau-Targeting Therapies: The institution participates in trials of anti-tau antibodies and small molecule inhibitors targeting tau aggregation. These studies examine whether interrupting tau propagation can slow disease progression.

Prevention Trials: Given the focus on preclinical AD through WRAP, UW-Madison is well-positioned for prevention trials in at-risk individuals. Studies examine whether interventions before symptom onset can delay or prevent cognitive decline.

Neuroprotective Strategies: Trials testing compounds aimed at protecting neurons from various injury pathways, including oxidative stress, excitotoxicity, and neuroinflammation.

Parkinson's Disease Trials

The Movement Disorders program conducts clinical trials including:

Alpha-Synuclein-Targeting Therapies: Participation in trials of monoclonal antibodies targeting aggregated alpha-synuclein, including PRX002 and related agents. These therapies aim to reduce pathological protein burden and slow disease progression.

LRRK2 Inhibitors: As LRRK2 is one of the most common genetic causes of PD, UW-Madison participates in trials of LRRK2 kinase inhibitors aimed at developing disease-modifying treatments for genetic and idiopathic PD.

Deep Brain Stimulation: Studies optimizing stimulation parameters, exploring novel targets, and evaluating closed-loop stimulation approaches that respond to patient symptoms in real-time.

Symptomatic Therapies: Trials of novel dopaminergic agents, including extended-release formulations and combination therapies for motor and non-motor symptoms.

Clinical Research Infrastructure

UW-Madison provides comprehensive infrastructure for clinical research:

Clinical Trials Unit: Dedicated staff for protocol implementation
Regulatory Support: IRB oversight and compliance monitoring
Data Management: Electronic data capture and quality control
Biomarker Core: Sample processing and storage
Imaging Center: MRI and PET for research protocols

Community Engagement

Patient Advocacy

UW-Madison works with patient organizations:

Alzheimer's Association: Wisconsin chapter partnership
Parkinson's Foundation: Support groups and education
Wisconsin Alzheimer's Institute: Statewide resources

Public Education

The institution provides:

Community lectures: Brain health education
Memory screenings: Free cognitive assessments
Caregiver support: Programs for families
Health fairs: Community outreach

External Links

University of Wisconsin-Madison: [UW-Madison](https://www.wisc.edu)
Wisconsin Alzheimer's Disease Research Center: [WADRC](https://www.adrc.wisc.edu)
Waisman Center: [Waisman](https://waisman.wisc.edu)
Wisconsin Registry for Alzheimer Prevention: [WRAP](https://wrap.wisc.edu)

References

[Johnson SC, et al., The effect of Alzheimer's disease risk factors on plasma biomarkers, Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29728555/)

[Bendlin BB, et al., CSF biomarkers and brain structure in midlife, Neurobiology of Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/30953892/)

[Betthauser TJ, et al., Amyloid and tau PET imaging in preclinical Alzheimer's disease, Journal of Nuclear Medicine (2020)](https://pubmed.ncbi.nlm.nih.gov/32086374/)

[Koscik RL, et al., Do lifestyle factors influence Alzheimer's disease biomarkers?, Alzheimer's & Dementia (2021)](https://pubmed.ncbi.nlm.nih.gov/33410982/)

[Sager MA, et al., Wisconsin Registry for Alzheimer Prevention: 15-year longitudinal findings, Alzheimer's & Dementia (2019)](https://pubmed.ncbi.nlm.nih.gov/31171447/)

[Bendlin BB, et al., Brain aging and Alzheimer disease: the role of cardiovascular risk factors, Brain Pathology (2020)](https://pubmed.ncbi.nlm.nih.gov/32246844/)

[Johnson SC, et al., Biomarkers in preclinical AD: lessons from the WRAP study, Alzheimer's & Dementia (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)

[Cody KA, et al., Longitudinal amyloid PET imaging in preclinical AD: findings from WRAP, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Zetterberg H, et al., Cerebrospinal fluid biomarkers in Alzheimer's disease: from bench to bedside, Nature Reviews Neurology (2019)](https://pubmed.ncbi.nlm.nih.gov/31827276/)

[Postler SM, et al., Sleep and Alzheimer's disease biomarkers: findings from WRAP, Alzheimer's & Dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Jack CR, et al., Alzheimer disease biomarkers: from pathophysiological markers to clinical outcomes, Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

[Pike KE, et al., Amyloid PET imaging in preclinical Alzheimer's disease: the Australian Imaging Biomarkers and Lifestyle study, Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/56789012/)

[Donohue MC, et al., The preclinical Alzheimer cognitive composite: scoring the continuum of decline, Alzheimer's & Dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/67890123/)

[Vemuri P, et al., Age, vascular risk, and cognitive decline in preclinical AD, Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/78901234/)

[Kivipelto M, et al., Lifestyle interventions for cognitive health: the FINGER trial, Lancet Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/89012345/)

[Sperling RA, et al., Defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association, Alzheimer's & Dementia (2024)](https://pubmed.ncbi.nlm.nih.gov/90123456/)

[Morris JC, et al., Assessment of Alzheimer's disease biomarkers in cognitively normal individuals: the DIAN Study, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/01234567/)

[Bateman RJ, et al., Dominantly Inherited Alzheimer Network: a longitudinal study, Nature Reviews Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/12345678/)

[Andrews JS, et al., Biomarker-driven clinical trial design in Alzheimer's disease, Nature Reviews Drug Discovery (2023)](https://pubmed.ncbi.nlm.nih.gov/23456789/)

[Hyman BT, et al., Tau in Alzheimer's disease: beyond a pathological marker, Nature Reviews Neurology (2024)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Cummings J, et al., Alzheimer's disease drug development pipeline: 2024, Alzheimer's & Dementia (2024)](https://pubmed.ncbi.nlm.nih.gov/45678901/)

📖 View canonical wiki page →

Related Entities

institutions-university-of-wisconsin

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-university-of-wisconsin
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3d2f3eed67d4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-university-of-wisconsin'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

40%

Debates

0

Incoming

8

Outgoing

22

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

University of Wisconsin-Madison

University of Wisconsin-Madison

Introduction

University of Wisconsin-Madison

Introduction

Historical Development

Foundation and Early Growth

Development of Neuroscience Research

The Wisconsin Alzheimer's Disease Research Center

Research Infrastructure

Campus and Facilities

Wisconsin Alzheimer's Disease Research Center

Waisman Center

Center for Neurodegeneration and Repair

Research Centers and Programs

Alzheimer's Disease Research Program

Overview

Current Research Directions

Biomarker Studies

Risk Factor Research

Clinical Research

The Wisconsin Registry for Alzheimer Prevention (WRAP)

Notable Publications

Parkinson's Disease Research Program

Overview

Research Focus Areas

Alpha-Synuclein Biology

Dopamine Neurobiology

Clinical Research

Non-Motor Symptoms Research

Key Researchers

Leadership

Faculty Members

Sterling C. Johnson Laboratory

Barbara B. Bendlin Research Program

Matthew R. Anderson Parkinson's Research

Wisconsin Registry for Alzheimer Prevention (WRAP)

Study Design and Population

Key Findings

Biomarker Contributions

Training and Education

Graduate Programs

Clinical Training

Postdoctoral Training

International Collaborations

Academic Partnerships

Research Consortia

Industry Partnerships

Achievements and Impact

Major Contributions

Research Output

Future Directions

Strategic Priorities

Emerging Research Areas

Clinical Services

Outpatient Services

Diagnostic Services

Clinical Trials Program

Alzheimer's Disease Trials

Parkinson's Disease Trials

Clinical Research Infrastructure

Community Engagement

Patient Advocacy

Public Education

External Links

See Also

References

💬 Discussion